Literature DB >> 15117950

Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations.

C Kenneth Kassenbrock1, Steven M Anderson.   

Abstract

c-Cbl down-regulates receptor tyrosine kinases by conjugating ubiquitin to them, leading to receptor internalization and degradation. The ubiquitin protein ligase activity of c-Cbl (abbreviated as E3 activity) is mediated by its RING finger domain. We show here that the E3 activity of c-Cbl is negatively regulated by other domains present in the amino-terminal half of the protein (the TKB and linker helix domains) and that this negative regulation is removed when the protein is phosphorylated on tyrosine residues. Protease digestion studies indicate that tyrosine phosphorylation alters the conformation of c-Cbl. We also show that mutation of certain conserved tyrosine residues to glutamate can constitutively activate the E3 activity of c-Cbl. In particular, a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor (EGFR). The Y371E mutant also has altered protease sensitivity from wild type, instead resembling the proteolytic pattern seen with tyrosine-phosphorylated c-Cbl. Mutation of the homologous tyrosine residue in Cbl-b to glutamate also leads to E3 activation while retaining EGFR-binding ability. These studies argue that Tyr-371 plays a key role in activating the E3 activity of c-Cbl and that the Y371E mutant may partially mimic phosphorylation at that site. However, Tyr-371 point mutants of c-Cbl are still able to undergo phosphorylation-induced E3 activation, and we show that Tyr-368 can also be phosphorylated in addition to Tyr-371, and contributes to activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117950     DOI: 10.1074/jbc.M404114200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl.

Authors:  Hao Dou; Lori Buetow; Andreas Hock; Gary J Sibbet; Karen H Vousden; Danny T Huang
Journal:  Nat Struct Mol Biol       Date:  2012-01-22       Impact factor: 15.369

2.  Cbl exposes its RING finger.

Authors:  Stephen C Kales; Philip E Ryan; Stanley Lipkowitz
Journal:  Nat Struct Mol Biol       Date:  2012-02-03       Impact factor: 15.369

Review 3.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Authors:  Stephen C Kales; Philip E Ryan; Marion M Nau; Stanley Lipkowitz
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 4.  Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.

Authors:  Mainak Guharoy; Pallab Bhowmick; Peter Tompa
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

5.  Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.

Authors:  Scott A Nadeau; Wei An; Bhopal C Mohapatra; Insha Mushtaq; Timothy A Bielecki; Haitao Luan; Neha Zutshi; Gulzar Ahmad; Matthew D Storck; Masashi Sanada; Seishi Ogawa; Vimla Band; Hamid Band
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

Review 6.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

7.  Juvenile myelomonocytic leukemia due to a germline CBL Y371C mutation: 35-year follow-up of a large family.

Authors:  Anand Pathak; Alexander Pemov; Mary L McMaster; Ramita Dewan; Sarangan Ravichandran; Evgenia Pak; Amalia Dutra; Hyo Jung Lee; Aurelie Vogt; Xijun Zhang; Meredith Yeager; Stacie Anderson; Martha Kirby; Neil Caporaso; Mark H Greene; Lynn R Goldin; Douglas R Stewart
Journal:  Hum Genet       Date:  2015-05-05       Impact factor: 4.132

Review 8.  Cell regulation by phosphotyrosine-targeted ubiquitin ligases.

Authors:  Jonathan A Cooper; Tomonori Kaneko; Shawn S C Li
Journal:  Mol Cell Biol       Date:  2015-03-16       Impact factor: 4.272

9.  Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

Authors:  Michael A Caligiuri; Roger Briesewitz; Jianhua Yu; Lisheng Wang; Min Wei; Kristy J Arnoczky; Trent B Marburger; Jing Wen; Danilo Perrotti; Clara D Bloomfield; Susan P Whitman
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

10.  Cbl negatively regulates JNK activation and cell death.

Authors:  Andrew A Sproul; Zhiheng Xu; Michael Wilhelm; Stephen Gire; Lloyd A Greene
Journal:  Cell Res       Date:  2009-08       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.